Explore leading companies in the Life Sciences & BioTech category. Discover market leaders, emerging players, and innovative companies shaping this industry.
Filter by Tags
Available Tags
Agriculture
Ai Powered
Analytics
Api First
Asia Pacific
Automation
B2b
B2b2c
B2c
Cloud Native
Data Warehouse
Decacorn
Developer Tools
Energy
Enterprise
Europe
Fortune500
Global
Hardware
Healthtech
Infrastructure
Iot
Manufacturing
Marketplace
North America
Open Source
Platform
Public
Saas
Scaleup
Services
Startup
Supply Chain
Technology
Unicorn
Us Only
All Life Sciences & BioTech Brands
| Brand ↑ | Tags | Revenue | Market Share | Description |
|---|---|---|---|---|
| 10x Genomics | B2bGlobalPublicEnterpriseHealthtechHardwareAnalyticsPlatform | $642M | - | Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms power cell-type discovery in oncology, neuroscience... |
| AbCellera | B2bGlobalPublicHealthtechAi PoweredPlatformAnalytics | $75M | - | Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase ... |
| Absci | Ai PoweredTechnologyStartupHealthtechPlatformPublicB2b | - | - | Absci is an AI drug creation company that combines generative AI with a synthetic biology platform to design novel therapeutic proteins from the groun... |
| Addition Therapeutics | HealthtechB2b | - | - | Emerged from stealth with $100M (Dec 2025) backed by Gates Foundation, SR One, Abingworth. PRINT LNP platform integrates RNA at specific genomic loci ... |
| Advanced Microbubbles | HealthtechStartupNorth AmericaB2bHardwareTechnology | - | - | Advanced Microbubbles develops ultrasound-activated microbubble technology for targeted drug and gene delivery, with a primary focus on oncology; micr... |
| Aerska Therapeutics | HealthtechB2b | - | - | Raised $39M (Feb 2026, doubled from $21M Series A). Brain-shuttle + RNAi delivery for genetic Alzheimer's and Parkinson's. Non-viral CNS delivery cros... |
| Aevice Health | HealthtechIotAi PoweredStartupB2b | - | - | Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing ... |
| Agomab Therapeutics | HealthtechB2b | - | - | Nasdaq IPO Feb 2026 (~$200M raised, ~$780M valuation, ticker AGMB). Positive Phase 2a data for ontunisertib in fibrostenosing Crohn's. Phase 1 data fo... |
| Aignostics | B2bAi PoweredHealthtechEuropeStartupAnalyticsPlatformSaas | - | - | Aignostics is a Berlin-based computational pathology company applying AI to histopathology image analysis for drug development and clinical diagnostic... |
| Alamar Biosciences | B2bHealthtechAi PoweredHardwareStartupNorth AmericaAnalytics | - | - | Alamar Biosciences develops the NULISA proteomics platform for ultrasensitive protein biomarker detection from minimal sample volumes; enables early d... |
| Alto Neuroscience | HealthtechB2b | - | - | Nasdaq-listed (ANRO). Raised $120M PIPE (2026) to fund ALTO-207 Phase 2b. FDA Fast Track for ALTO-101. Biomarker-stratified psychiatry matching patien... |
| Altos Labs | HealthtechB2bStartupTechnologyGlobalNorth AmericaEuropeAnalytics | - | - | Altos Labs is a longevity biotech company focused on cellular rejuvenation programming to reverse disease and extend healthspan; raised $3B at launch ... |
| Alumis | B2bHealthtechStartupNorth AmericaPublicAnalytics | - | - | Alumis is a clinical-stage biopharmaceutical company developing oral TYK2 inhibitors for immune-mediated diseases including psoriasis, lupus, and infl... |
| Alveus Therapeutics | HealthtechTechnologyStartupB2bGlobal | - | - | Alveus Therapeutics raised $150M Series A in 2025 for inhaled mRNA therapeutics targeting pulmonary diseases including idiopathic pulmonary fibrosis a... |
| Alzheon | HealthtechStartupNorth AmericaB2bPlatform | - | - | Alzheon is a clinical-stage biotech developing ALZ-801, an oral amyloid oligomer inhibitor for Alzheimer's disease prevention in genetically at-risk p... |
| Amplitude Vascular Systems | B2bHealthtechHardwareStartupNorth AmericaTechnology | - | - | Amplitude Vascular Systems (AVS) is a medical device company developing the Pulse IVL system — a high-frequency pulsatile pressure wave device for tre... |
| Areteia Therapeutics | B2bHealthtechStartupNorth AmericaTechnology | - | - | Areteia Therapeutics (formerly TPI) is developing dexpramipexole, an oral eosinophil-depleting drug for eosinophilic asthma and EGPA; raised $215M in ... |
| Artiva Biotherapeutics | B2bHealthtechStartupNorth AmericaPublic | - | - | Artiva Biotherapeutics develops off-the-shelf allogeneic natural killer (NK) cell therapies for cancer; lead program AB-101 targets B-cell malignancie... |
| Asimov | B2bHealthtechAi PoweredDeveloper ToolsSaasStartupNorth AmericaAnalytics | - | - | Asimov develops software and AI tools for mammalian cell engineering to accelerate design and manufacturing of biologics and gene therapies; combines ... |
| Athos Therapeutics | HealthtechAi PoweredStartupEuropeB2bOpen Source | - | - | Athos Therapeutics is a UK clinical-stage biotech founded in 2019 using AI and systems biology to discover precision therapies for autoimmune and chro... |
| Atomic AI | HealthtechAi PoweredStartupNorth AmericaB2bAnalytics | - | - | Atomic AI is a San Francisco biotech using AI and structural biology to design RNA-targeting therapeutics; founded in 2021 by Raphael Townshend (Alpha... |
| Axtria | AnalyticsAi PoweredB2bSaasEnterpriseHealthtechCloud NativeGlobalPlatform | - | - | Axtria delivers AI-powered analytics and commercial software to 16 of the top 20 global life sciences companies; recognized in two Gartner Hype Cycle ... |
| Be Biopharma | HealthtechB2b | - | - | $274M total raised including $92M Series C with Bristol Myers Squibb. Phase 1/2 active for BE-101 in Hemophilia B. CRISPR-engineered B cells as contin... |
| Beam Therapeutics | StartupTechnologyHealthtechPublicB2b | - | - | Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double h... |
| Beckley Psytech | HealthtechStartupB2bTechnologyEurope | - | - | Beckley Psytech (now AtaiBeckley) achieved FDA Breakthrough Therapy Designation for BPL-003 (5-MeO-DMT nasal spray) for treatment-resistant depression... |
| BenchSci | B2bAi PoweredHealthtechSaasPlatformAnalyticsStartupScaleupNorth AmericaEnterprise | - | - | BenchSci is an AI-powered biomedical research intelligence platform used by 16 of the top 20 pharma companies; accelerates experiment design by analyz... |
| BillionToOne | HealthtechAi PoweredPublicNorth AmericaB2bPlatform | - | - | IPO Nov 2025 (BLLN, Nasdaq); $273M raised; 508K+ tests in 2025; $293–299M revenue guidance FY2025.... |
| BioAge Labs | HealthtechB2bPublicNorth AmericaStartup | - | - | Clinical-stage biotech targeting metabolic aging for obesity and muscle-wasting disorders. IPO Sep 2024 (Nasdaq: BIOA); $198M raised; lead program aze... |
| BioNTech | B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform | - | - | German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;... |
| bit.bio | B2bHealthtechPlatformStartupEuropeTechnologyOpen Source | - | - | bit.bio is a Cambridge, UK synthetic biology company using its proprietary opti-ox technology to reprogram stem cells into any human cell type at scal... |
| Bluejay Therapeutics | HealthtechB2bNorth AmericaStartupScaleupAsia Pacific | - | - | Bluejay Therapeutics is a clinical-stage biopharmaceutical company developing therapies for chronic hepatitis B and liver diseases; raised over $100M;... |
| BostonGene | B2bHealthtechAi PoweredAnalyticsEnterprise | - | - | BostonGene is an AI-powered precision oncology company using multiomics and tumor microenvironment analysis to guide cancer treatment; won Frost & Sul... |
| BrightHeart | HardwareHealthtechB2b | - | - | Raised €11M Series A (Jan 2026). FDA-cleared in 2025. Detects 96%+ of congenital heart defects in prenatal ultrasound. Distributed via GE HealthCare V... |
| C16 Biosciences | B2bStartupNorth AmericaTechnologyAgricultureSupply ChainEnergy | - | - | C16 Biosciences produces Palmless, a biofermentation-derived alternative to palm oil targeting the beauty, personal care, and food industries; raised ... |
| Caidya | B2bHealthtechGlobalEnterpriseServicesAsia PacificNorth AmericaScaleup | - | - | Caidya is a global mid-sized CRO formed from the merger of dMed Global and Clinipace; operates in 20+ countries across 50+ regions; raised $165M from ... |
| Cambrian Bio | HealthtechStartupB2bNorth AmericaPlatformSaas | - | - | Cambrian Bio is a New York-based clinical-stage biopharmaceutical company founded in 2019 that develops therapeutics targeting the biology of aging; o... |
| Capstan Therapeutics | HealthtechB2bStartupNorth AmericaAi PoweredPlatformHardware | - | - | Capstan Therapeutics develops in vivo RNA-based therapies using targeted lipid nanoparticles to engineer immune cells inside the body without ex vivo ... |
| Cellanome | HealthtechB2bStartupNorth AmericaHardwareAnalyticsPlatformAi Powered | - | - | Cellanome is building a multi-omics platform combining genome sequencing, microfluidics, and integrated sensors to measure biological data at single-c... |
| Cellares | B2bHealthtechHardwareManufacturingStartupGlobalNorth AmericaEuropeAsia Pacific | - | - | Cellares is the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy, automating end-to-end CAR-T and cell therapy prod... |
| Cerevance | B2bB2cHealthtechStartupNorth AmericaScaleup | - | - | Cerevance is a CNS drug discovery company using proprietary NETSseq single-nucleus transcriptomics to identify cell-type-specific drug targets in huma... |
| ChromaCode | HealthtechAi PoweredAnalyticsB2bPlatformTechnologySaasStartupGlobal | - | - | ChromaCode develops HDPCR technology enabling standard PCR instruments to run highly multiplexed molecular diagnostic assays for infectious disease, o... |
| Circle Pharma | B2bHealthtechTechnologyNorth AmericaStartupScaleup | - | - | Circle Pharma develops orally deliverable macrocycle drug candidates targeting intracellular protein-protein interactions in cancer; raised $90M Serie... |
| Clasp Therapeutics | HealthtechB2bStartupTechnologyNorth America | - | - | Clasp Therapeutics develops tumor-specific T cell engagers targeting mutant p53 and other cancer driver mutation peptides presented by HLA molecules, ... |
| Cognito Therapeutics | HardwareHealthtechB2b | - | - | Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device... |
| Colossal Biosciences | StartupB2bAnalyticsAi PoweredNorth AmericaDecacorn | - | - | Colossal Biosciences is the world's first de-extinction company; $555M raised, $10.2B decacorn valuation; targeting woolly mammoth embryos by 2026, di... |
| ConcertAI | HealthtechAi PoweredAnalyticsB2bSaasEnterpriseData WarehousePlatformUnicorn | - | - | ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 prof... |
| Cornerstone Robotics | HardwareHealthtechB2b | - | - | Raised $200M oversubscribed (Nov 2025) backed by Hong Kong Investment Corporation and sovereign wealth funds. China NMPA-approved. UK colorectal/urolo... |
| Cradle | HealthtechSaasNorth AmericaB2b | - | - | AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein enginee... |
| Cradle Bio | Ai PoweredStartupB2bSaasTechnologyHealthtech | - | - | Cradle provides an AI platform for protein engineering that accelerates the design of improved enzymes, antibodies, and other biologics for industrial... |
| CUTISS | B2bB2cHealthtechStartupEuropeScaleup | - | - | CUTISS is a Swiss biotech developing personalized dermo-epidermal skin grafts from patient cells for large skin defect treatment; denovoSkin product r... |
| Cytogel Pharma | HealthtechStartupNorth AmericaB2b | - | - | Cytogel Pharma is a clinical-stage biotech developing CYT-1010, a first-in-class endomorphin-based analgesic for non-addictive pain relief; targets th... |
| Cytotheryx | HealthtechB2b | - | - | Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bio-incubators for human hepatocyte production at sc... |
| Deep Genomics | B2bAi PoweredStartupNorth AmericaTechnologyAnalyticsPlatformHealthtech | - | - | Deep Genomics uses AI to discover and design RNA-based therapies for genetic diseases; its AI Workbench platform decodes RNA biology at scale; raised ... |
| Delfi Diagnostics | B2bHealthtechAi PoweredAnalyticsNorth AmericaStartupTechnology | - | - | Delfi Diagnostics has raised $332M total to develop blood-based cancer detection using whole-genome cfDNA fragmentation analysis and ML; clinically va... |
| Detect | HealthtechB2cB2bHardwareNorth AmericaTechnologyAi Powered | - | - | Detect pioneered the FDA-authorized rapid at-home molecular COVID-19 test and is now developing a second-gen molecular diagnostics platform targeting ... |
| Dewpoint Therapeutics | B2bHealthtechAi PoweredStartupNorth AmericaAnalytics | - | - | Dewpoint Therapeutics pioneers drug discovery targeting biomolecular condensates — liquid-like protein assemblies implicated in cancer, neurodegenerat... |
| Disc Medicine | B2bB2cHealthtechStartupNorth AmericaPublic | - | - | Disc Medicine is a Nasdaq-listed clinical-stage biopharma focused on hematologic diseases including polycythemia vera and myelofibrosis; lead asset bi... |
| DNA Script | B2bHealthtechHardwareEuropeGlobalStartupTechnologyManufacturing | - | - | DNA Script has raised $335M total including a $165M oversubscribed Series C; received CE Mark in 2025 for SYNTAX System in clinical labs across Europe... |
| DNAnexus | B2bSaasHealthtechCloud NativeAnalyticsEnterprisePlatformGlobalAi PoweredInfrastructure | - | - | DNAnexus is the leading precision health data cloud, managing 65+ petabytes of biomedical data for 12,000+ users across 48 countries; $200M Series I l... |
| Dotmatics | - | - | - | Dotmatics (acquired by Insightful Science 2024) serves 1M+ researchers at 10,000+ organizations; R&D data management and scientific informatics platfo... |
| Dyno Therapeutics | B2bHealthtechAi PoweredStartupNorth AmericaAnalytics | - | - | Dyno Therapeutics uses AI and high-throughput synthesis to engineer next-generation AAV gene therapy vectors with improved tissue targeting, manufactu... |
| Earendil Labs | HealthtechB2b | - | - | Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 20... |
| eGenesis | HealthtechB2b | - | - | FDA-cleared IND for CRISPR-edited pig kidney (ESKD Phase 1/2/3). First patient dialysis-free at 7+ months post-transplant. 69-gene-edited pig — most c... |
| Eikon Therapeutics | HealthtechB2b | - | - | Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks single protein molecules in living cells. Creates ... |
| Element Biosciences | B2bHardwarePlatformNorth AmericaAnalyticsGlobalScaleupAi Powered | - | - | Element Biosciences makes the AVITI benchtop DNA sequencer; raised $277M Series D in 2024 (led by Wellington Management, Samsung) for $680M+ cumulativ... |
| Elligo Health Research | B2bHealthtechPlatformSaasNorth AmericaStartupAnalyticsAi Powered | - | - | Elligo Health Research brings clinical trials into healthcare settings by using EHR data for patient identification and providing site infrastructure;... |
| Emerald Cloud Lab | B2bSaasCloud NativePlatformAutomationApi FirstOpen SourceAi PoweredNorth America | $15M | - | Emerald Cloud Lab offers a fully remote, cloud-controlled laboratory with 200+ instrument models; ~$15M ARR as of 2025 with labs in the U.S. and expan... |
| Emulate | HealthtechB2bEnterpriseAi PoweredHardwarePlatformStartupScaleupGlobalNorth America | - | - | Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system ... |
| Encapsulate Bio | HealthtechB2bStartupNorth AmericaAi Powered | - | - | Encapsulate Bio develops tumor-on-a-chip microfluidic platforms that test patient-derived tumor samples against cancer therapies to guide personalized... |
| Endeavor Biomedicines | B2bHealthtechStartupNorth America | - | - | Endeavor Biomedicines is a Cambridge-based clinical-stage biotech targeting drivers of fibrosis and oncology with precision small molecules; raised $4... |
| Enterprise Therapeutics | B2bHealthtechEuropeStartup | - | - | Enterprise Therapeutics is a UK-based drug discovery biotech targeting ion channels and mucus biology to treat cystic fibrosis, COPD, and non-CF bronc... |
| Enveda Biosciences | B2bHealthtechAi PoweredStartupNorth AmericaScaleup | - | - | Enveda Biosciences uses AI, metabolomics, and robotics to mine natural products for novel drug candidates; platform identifies chemical structure and ... |
| EpiBiologics | HealthtechB2b | - | - | Raised $107M Series B (Jan 2026) co-led by J&J Ventures and Google Ventures. EpiTAC targets membrane and secreted proteins — expanding degradation bey... |
| ET Healthcare | B2bHealthtechHardwareStartupNorth America | - | - | ET Healthcare develops isotachophoresis (ITP) technology for rapid, automated nucleic acid and biomarker sample preparation in life sciences research ... |
| Evolved by Nature | B2bHealthtechManufacturingAgricultureStartupNorth AmericaPlatform | - | - | Evolved by Nature has developed Activated Silk technology — a green chemistry platform using natural silk proteins as sustainable, high-performance in... |
| Evozyne | B2bStartupAi PoweredTechnologyNorth AmericaHealthtech | - | - | Evozyne applies generative AI and evolutionary principles to design novel therapeutic proteins; raised $144M total including $81M Series B led by Fide... |
| Finch Therapeutics | StartupHealthtechTechnologyPublicB2b | - | - | Finch Therapeutics develops microbiome-based medicines targeting the gut-brain and gut-immune axis with programs in autism spectrum disorder and C. di... |
| Florence Healthcare | B2bSaasHealthtechEnterprisePlatformGlobalCloud NativeAnalytics | - | - | Florence Healthcare is the leading clinical trial site enablement platform, connecting 12,000+ research sites in 45 countries; $116M raised from Insig... |
| FogPharma | StartupHealthtechNorth AmericaTechnology | - | - | FogPharma develops cell-penetrating mini-proteins (CPMPs) to target intracellular cancer drivers like beta-catenin and FOXM1 that are undruggable by a... |
| Formation Bio | B2bHealthtechAi PoweredEnterpriseSaasPlatformNorth AmericaScaleupStartup | - | - | Formation Bio is an AI-native pharmaceutical company that acquires clinical-stage drug assets and accelerates their development to market using propri... |
| ForSight Robotics | HardwareHealthtechB2b | - | - | Ophthalmic robotics company raised $125M Series B in Jun 2025; first human cataract trials launching 2026;... |
| Freenome | HealthtechAi PoweredB2bB2cNorth AmericaStartupPlatformAnalytics | - | - | Freenome is a biotech company developing AI-powered multiomics blood tests for early cancer detection; raised $1.1B+ total with Roche as a major inves... |
| Frontier Bio | B2bStartupHealthtechNorth AmericaAi Powered | - | - | Frontier Bio develops living vascular grafts and bioprinted human tissue for pharmaceutical testing and future organ donation, using a 4D self-assembl... |
| Frontier Medicines | B2bHealthtechAi PoweredStartupNorth AmericaScaleupPlatformTechnology | - | - | Frontier Medicines is a precision medicine biotech targeting previously undruggable disease-causing proteins using chemoproteomics and covalent chemis... |
| Gameto | HealthtechTechnologyStartupB2bGlobal | - | - | Gameto raised $70M Series B in 2024 for its stem cell technology that dramatically reduces IVF stimulation duration from 10 days to 2–3 days, making f... |
| GATC Health | B2bAi PoweredHealthtechAnalyticsPlatformNorth AmericaStartupSaas | - | - | GATC Health uses its Multiomics Advanced Technology (MAT) platform to simulate human biochemistry and accelerate drug discovery; its AI achieves 86% s... |
| Genentech | B2bGlobalEnterprisePublicHealthtechManufacturingFortune500 | - | - | Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avasti... |
| Genesis Therapeutics | B2bAi PoweredHealthtechNorth AmericaStartupPlatformAnalytics | - | - | Genesis Therapeutics (now Genesis Molecular AI) is a biotech company applying AI to small molecule drug discovery; raised $200M Series B in 2025 led b... |
| GenScript ProBio | B2bHealthtechAsia PacificGlobalEnterpriseManufacturingPlatformTechnology | - | - | GenScript ProBio is the CDMO subsidiary of GenScript Biotech, offering gene synthesis, biologics development, cell therapy manufacturing (CAR-T), and ... |
| HeartFlow | HealthtechAi PoweredB2bPublicTechnologyPlatform | - | - | HeartFlow creates AI-powered, non-invasive 3D models of coronary arteries from CT scans to guide treatment of coronary artery disease, with FDA cleara... |
| Hemab Therapeutics | HealthtechB2b | - | - | Raised $157M oversubscribed Series C (Oct 2025) led by Sofinnova and Qatar Investment Authority. Sutacimig entering registration study 2026 for Glanzm... |
| Huisheng Pharmaceutical | HealthtechManufacturingAsia PacificB2bB2cServicesGlobal | - | - | Huisheng Pharmaceutical is a Chinese pharma company specializing in traditional Chinese medicine and modern drug formulations; operates across R&D, ma... |
| Illumina | B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500 | $4.34B | 80% | World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and populatio... |
| ImmunoVec | HealthtechB2b | - | - | Received up to $40.7M ARPA-H award (Oct 2025). Polymeric nanoparticle platform to reprogram immune cells in vivo without viral vectors. Non-viral deli... |
| INBRAIN Neuroelectronics | HealthtechHardwareStartupEuropeB2bAi PoweredTechnology | - | - | INBRAIN Neuroelectronics develops graphene-based brain-computer interfaces for AI-driven, adaptive neuromodulation; raised €30M Series B in 2024; targ... |
| Inceptive | B2bHealthtechAi PoweredStartupEuropeNorth AmericaAnalytics | - | - | Inceptive designs synthetic RNA molecules for therapeutic applications using deep learning and high-throughput experiments; targets mRNA medicines, RN... |
| Infant Bacterial Therapeutics | HealthtechTechnologyStartupB2bPublic | - | - | Infant Bacterial Therapeutics (IBT) is developing live biotherapeutic Lactobacillus reuteri DSM17938 for necrotizing enterocolitis prevention in prema... |
| Insilico Medicine | B2bHealthtechSaasPublic | $56.2M | - | Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover ... |
| Insitro | Ai PoweredStartupTechnologyAnalyticsHealthtechB2b | - | - | Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised $400M+ to build proprietary biological datasets fo... |
| InterVenn Biosciences | HealthtechAi PoweredB2bStartupAnalyticsNorth America | - | - | InterVenn Biosciences pioneered clinical glycoproteomics with AI-powered liquid biopsy diagnostics for cancer; raised $251M total, received AMA PLA co... |
| Kailera Therapeutics | B2bHealthtechSaas | - | - | Kailera Therapeutics (Hengrui spinout) raised $1B+ and filed a US IPO (Mar 2026); its lead GLP-1/GIP drug showed 18% weight loss in Phase 3, competing... |
| Karius | HealthtechAi PoweredB2bEnterpriseNorth AmericaTechnologyAnalytics | - | - | Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Kar... |
| Kriya Therapeutics | B2bHealthtechTechnologyNorth AmericaStartupScaleup | - | - | Kriya Therapeutics is a gene therapy company using AAV vector engineering to develop one-time treatments for chronic diseases including diabetes and h... |
| Kumquat Biosciences | B2bHealthtechStartupNorth America | - | - | Kumquat Biosciences is an oncology-focused drug discovery company developing novel cancer therapeutics through internal research programs and academic... |
| Labviva | MarketplaceB2bHealthtechPlatformSaasSupply ChainEnterpriseNorth AmericaStartupApi First | - | - | Labviva is a digital procurement marketplace for life sciences researchers, connecting labs at academic institutions and biopharma companies with scie... |
| Life Biosciences | HealthtechB2b | - | - | Closed $80M Series D (Apr 2026). FDA-cleared IND for ER-100 in optic neuropathies (Jan 2026). Phase 1 enrolling. Co-founded by Harvard's David Sinclai... |
| Lightship | B2bHealthtechPlatformStartupNorth AmericaGlobalTechnologyServices | - | - | Lightship is a clinical research organization (CRO) specializing in decentralized and hybrid clinical trial design, combining in-clinic visits, at-hom... |
| LinusBio | HealthtechAi PoweredStartupNorth AmericaAnalyticsPlatformB2b | - | - | LinusBio is a precision medicine company using AI-powered exposome sequencing of hair samples to detect environmental and genetic disease risk factors... |
| Loyal | HealthtechStartupNorth AmericaB2cAi PoweredPlatform | - | - | Loyal is a veterinary biotech developing FDA-regulated longevity drugs for dogs; its lead drug LOY-001 received FDA reasonable expectation of effectiv... |
| Lyell Immunopharma | StartupTechnologyHealthtechPublicB2b | - | - | Lyell Immunopharma develops next-generation CAR-T cell therapies designed to overcome T cell exhaustion and treat solid tumors, the frontier of cell t... |
| Mammoth Biosciences | HealthtechAi PoweredStartupNorth AmericaB2b | - | - | Mammoth Biosciences is a CRISPR gene editing company co-founded by Nobel laureate Jennifer Doudna; pioneered NanoCas — the first efficient ultracompac... |
| Mantis Biotech | HealthtechB2b | - | - | YC-backed AI company raised $48M Series A co-led by a16z Bio and GV in Feb 2026; builds digital twins of human physiology to generate diverse syntheti... |
| MasterControl | SaasB2bEnterprisePlatformNorth AmericaManufacturingAi PoweredHealthtechAnalytics | $200M | - | MasterControl is the leading QMS and MES platform for regulated life sciences industries, serving 1,100+ companies with $200M revenue in 2025; valued ... |
| Maze Therapeutics | B2bB2cHealthtechStartupNorth AmericaAi PoweredScaleup | - | - | Maze Therapeutics is a clinical-stage precision medicine company using human genetics to develop small-molecule drugs for chronic kidney disease and o... |
| Microbiotica | HealthtechTechnologyStartupB2bGlobal | - | - | Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products... |
| Mirador Therapeutics | HealthtechB2b | - | - | Raised $250M Series B (Jan 2026). $650M+ total raised. Mirador360 genetics-first platform. 10+ clinical readouts by end of 2027. Pipeline spans Crohn'... |
| Muna Therapeutics | HealthtechTechnologyStartupB2bGlobal | - | - | Muna Therapeutics raised $75M in 2024 targeting microglial biology in Alzheimer's disease, using iPSC-derived microglia models to identify novel drug ... |
| Nautilus Biotechnology | StartupTechnologyHealthtechAnalyticsPlatformPublicB2b | - | - | Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the full human proteome at a scale and sensitivity previo... |
| NEOK Bio | HealthtechTechnologyStartupB2bGlobal | - | - | NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in Alzheimer's disease and ALS using a novel class of ... |
| Neuralink | HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise | - | - | Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9... |
| Neurelis | HealthtechB2bB2cGlobalSaas | - | - | Neuroscience pharma commercializing VALTOCO (diazepam nasal spray) for seizure clusters. ~$295-300M estimated net sales in 2025; 30%+ EBITDA margin; n... |
| Neuron23 | HealthtechAi PoweredStartupNorth AmericaB2b | - | - | $96.5M Series D (2025); NEU-411 LRRK2 inhibitor in Phase 2 NEULARK trial for early Parkinson's disease.... |
| Neurona Therapeutics | StartupHealthtechNorth AmericaTechnology | - | - | Neurona Therapeutics develops interneuron cell therapies derived from human iPSCs to repair dysregulated neural circuits; lead program NRTX-1001 is in... |
| NewLimit | HealthtechB2b | - | - | Raised $130M Series B (Kleiner Perkins) + $45M from Eli Lilly at $1.62B valuation. First demonstrated restoration of youthful killing function in aged... |
| NextPoint Therapeutics | HealthtechB2bStartupNorth AmericaGlobal | - | - | NextPoint Therapeutics is a clinical-stage immuno-oncology company targeting the HHLA2 checkpoint with two Phase 1 candidates (NPX267, NPX887); raised... |
| NOWDiagnostics | HealthtechB2bB2cHardwareManufacturingNorth AmericaStartupPlatform | - | - | NOWDiagnostics develops OTC and point-of-care rapid diagnostic tests using minimal capillary blood or saliva samples; produces the CLIP platform for s... |
| NRG Therapeutics | HealthtechB2b | - | - | Raised £50M ($67M) oversubscribed Series B (Sep 2025). First participants dosed in Phase 1 of NRG5051 (Jan 2026). Phase 1 readout expected end of 2026... |
| Numerion Labs | B2bAi PoweredSaasPlatformNorth AmericaHealthtechStartup | - | - | Numerion Labs (fka Atomwise) deploys AtomNet deep learning for ultra-fast virtual drug screening; partnered with Sanofi for up to $1.2B in milestones;... |
| Nusano | B2bHealthtechManufacturingSupply ChainStartupNorth AmericaHardware | - | - | Nusano is a Seattle-based startup developing a proprietary linear accelerator platform to produce uranium-free diagnostic and therapeutic radioisotope... |
| Nuvig Therapeutics | HealthtechB2bStartupTechnologyGlobal | - | - | Nuvig Therapeutics develops first-in-class Fc-fragment immunomodulators targeting endogenous regulatory pathways to treat autoimmune diseases without ... |
| Omniscient Neurotechnology | HealthtechAi PoweredHardwareB2bGlobalStartupAnalytics | - | - | Omniscient Neurotechnology (o8t) is the pioneer of clinical connectomics with its FDA-cleared Quicktome brain mapping platform; raised up to $36M Seri... |
| Opentrons | B2bHardwareOpen SourceAi PoweredPlatformGlobalStartupTechnology | - | - | Opentrons democratizes lab automation with 10,000+ OT-2 and Flex robotic systems deployed globally; raised $200M+ including $20M Series C in Nov 2025;... |
| Orbital Therapeutics | B2bHealthtechAi PoweredPlatformStartupNorth AmericaGlobal | - | - | Orbital Therapeutics is a next-gen RNA biotech that raised $270M Series A in 2023; advancing circular RNA and in vivo CAR-T programs for autoimmune di... |
| Orca Bio | B2bHealthtechStartupNorth AmericaAnalytics | - | - | Orca Bio is developing high-purity precision cell therapies using proprietary cell sorting technology to improve the safety and outcomes of bone marro... |
| Outpace Bio | B2bAi PoweredHealthtechStartupNorth America | - | - | Outpace Bio is a clinical-stage biotech using AI-powered protein design and synthetic biology to develop next-generation cell therapies targeting soli... |
| Oxford Nanopore Technologies | B2bGlobalPublicHealthtechHardwareAnalyticsPlatform | $223M | - | UK nanopore sequencing pioneer with portable MinION device; £223M FY2025 revenue (+24% constant currency). Clinical revenues up 60% as sequencing move... |
| Pacific Biosciences | B2bGlobalPublicHealthtechHardwareAnalyticsPlatform | $170M | - | Pioneer of single-molecule real-time (SMRT) long-read sequencing; Revio system targets clinical and research markets. Guides to $150–$170M FY2025 reve... |
| Paradromics | HealthtechStartupNorth AmericaHardwareAi PoweredTechnology | - | - | Paradromics is developing the Connexus fully implantable BCI for speech restoration in paralyzed patients; received FDA IDE approval and completed fir... |
| Pathway Genomics | HealthtechB2b2cPlatformNorth AmericaStartupAnalytics | - | - | CAP- and CLIA-accredited clinical genetic testing lab offering cancer risk, cardiac, pharmacogenomics, and wellness panels to physicians and patients;... |
| Persephone Biosciences | HealthtechB2bStartupNorth AmericaAi PoweredAnalytics | - | - | Persephone Biosciences uses gut microbiome profiling and synthetic biology to develop cancer immunotherapy response predictors and novel therapeutics;... |
| PhaseV | HealthtechB2b | - | - | Raised $50M Series A (May 2025) co-led by Accel and Insight Partners. Cuts trial costs 50%, enrollment 40%, duration 40%. 40+ pharma sponsors. 7 of wo... |
| Phlow | B2bStartupNorth AmericaManufacturingServices | - | - | Phlow raised $37M Series C in July 2025 and holds $600M+ in government contracts including a $354M BARDA contract; manufactures critical active pharma... |
| Pliant Therapeutics | HealthtechTechnologyPublicB2bStartup | - | - | Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in ... |
| Poplar Therapeutics | HealthtechB2b | - | - | Raised $95M total ($50M Series A Jan 2026 + $45M extension Mar 2026) from SR One, Vida, RA Capital, Janus Henderson. Triple-action anti-IgE mechanism.... |
| Prime Medicine | HealthtechB2b | - | - | Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing ... |
| Profluent Bio | Ai PoweredB2bHealthtechStartupTechnology | - | - | AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and ... |
| Prolific Machines | B2bHealthtechStartupNorth AmericaAi PoweredTechnologyManufacturing | - | - | Prolific Machines is a Berkeley-based biotech company using light to control cell growth and differentiation, dramatically reducing bioreactor costs f... |
| Rakuten Medical | B2bHealthtechTechnologyAsia PacificStartupScaleupPublic | - | - | Rakuten Medical is a biotech developing photoimmunotherapy cancer treatment using its Illuminox platform (cetuximab sarotalocan), approved in Japan fo... |
| Rapport Therapeutics | B2bHealthtechNorth AmericaStartupPublicPlatform | - | - | Rapport Therapeutics is a public clinical-stage biotech (Nasdaq: RAPP) developing precision small molecules targeting TARP-containing AMPARs for epile... |
| Regeneron | B2bGlobalPublicEnterpriseHealthtechManufacturingFortune500 | $14B | - | Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific dr... |
| Reify Health | B2bHealthtechSaasEnterprisePlatformNorth AmericaScaleupAnalyticsAi Powered | - | - | Reify Health raised $220M Series D at $4.8B valuation; OneStudyTeam and Care Access accelerate clinical trial site operations and decentralized enroll... |
| Relation Therapeutics | HealthtechStartupB2bAi PoweredEuropePlatformTechnology | - | - | Relation Therapeutics uses its Lab-in-the-Loop AI platform to discover novel drug targets; secured a $1.7B multi-program Novartis collaboration and a ... |
| Relay Therapeutics | B2bStartupHealthtechAi PoweredPlatform | - | - | Cambridge MA precision oncology biotech using Dynamo platform to exploit protein motion for drug design; lead asset RLY-2608 targets PI3Kα in breast c... |
| Retro Biosciences | HealthtechB2b | - | - | Largest-funded pure-play longevity startup raising $1B Series A at $5B valuation; Sam Altman-backed; pursuing cellular reprogramming, autophagy, and p... |
| ROME Therapeutics | HealthtechStartupB2bAnalyticsNorth AmericaAi Powered | - | - | ROME Therapeutics pioneers drugs targeting the dark genome — genomic repeats implicated in cancer and autoimmune disease; raised ~$200M backed by J&J,... |
| Rubedo Life Sciences | HealthtechB2b | - | - | $40M Series A. First patient dosed in Phase 1 for RLS-1496 — first GPX4 modulator targeting pathological senescent cells via ferroptosis. Novel senoly... |
| Saama Analytics | B2bHealthtechAi PoweredSaasAnalyticsEnterpriseNorth AmericaPlatformData WarehouseScaleup | - | - | Saama Analytics is the #1 AI clinical analytics platform for life sciences; received up to $430M Carlyle-led investment in May 2025; serves 50+ biotec... |
| Saluda Medical | HealthtechHardwareB2bGlobalStartupAi Powered | - | - | Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M... |
| Sana Biotechnology | StartupHealthtechTechnologyPublicB2b | - | - | Sana Biotechnology develops engineered cell and gene therapies with fusogen delivery technology to treat serious diseases through in vivo and ex vivo ... |
| Schrödinger | B2bGlobalPublicEnterpriseHealthtechAi PoweredSaasPlatformAnalytics | - | - | Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue up 54% YoY; $150M Novartis collaboration signed in ... |
| Scipher Medicine | HealthtechAi PoweredAnalyticsB2bStartupNorth AmericaPlatform | - | - | Scipher Medicine uses AI and network medicine to match autoimmune patients to effective therapies; PrismRA is the first molecular test approved to pre... |
| Scribe Therapeutics | HealthtechB2b | - | - | Raised $100M Series B. Jennifer Doudna co-founder. Sanofi + Eli Lilly partnerships. STX-1150 (PCSK9 silencing via CasX-ELXR) IND projected mid-2026 — ... |
| Seismic Therapeutic | B2bHealthtechAi PoweredStartupNorth America | - | - | Seismic Therapeutic raised $222M+ total ($121M Series B in 2023, $25M in 2025) using its IMPACT ML platform; dosed first patient in Phase 1 for S-4321... |
| Selkirk Pharma | B2bManufacturingHealthtechServicesNorth AmericaStartupUs Only | - | - | Selkirk Pharma is a US-based CDMO specializing in aseptic fill/finish for sterile injectable drug products; raised $82M+ total; operates a 115,000 sq ... |
| Seres Therapeutics | StartupHealthtechTechnologyPublicB2b | - | - | Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral microbiome medicine for preventing recurrent C. diff... |
| SHINE Technologies | EnergyHealthtechManufacturingHardwareStartupNorth AmericaB2b | - | - | SHINE Technologies uses fusion neutron technology to produce medical isotopes; received a conditional $263M DOE loan in April 2026 to complete the Chr... |
| Shoreline Biosciences | HealthtechB2bStartupNorth America | - | - | iPSC-derived allogeneic NK cell and macrophage immunotherapy platform. $183M raised; $300M+ total with partnerships; SMART manufacturing for off-the-s... |
| Shorla Oncology | HealthtechB2bStartupEuropeNorth America | - | - | Shorla Oncology is a specialty pharma focused on oncology and rare/pediatric cancers; reformulates approved therapies to address drug shortages; raise... |
| Sidewinder Therapeutics | HealthtechTechnologyStartupB2bGlobal | - | - | Sidewinder Therapeutics raised $100M Series A in 2025 for its conditional activation platform that creates tumor-selective cancer drugs that only beco... |
| Sionna Therapeutics | HealthtechB2bStartupNorth AmericaPlatformAi Powered | - | - | Sionna Therapeutics is developing next-generation small molecule CFTR modulators targeting full restoration of CFTR protein function in cystic fibrosi... |
| Solve Therapeutics | HealthtechB2b | - | - | Raised $120M oversubscribed (Nov 2025) with Merck & Co. as new equity investor. $321M total. CloakLink ADC technology reduces hydrophobicity and toxic... |
| SpliceBio | HealthtechB2b | - | - | Raised $135M Series B led by Sanofi Ventures and EQT (Jun 2025). First patient dosed in Phase 1/2 for Stargardt disease (Jan 2026). Overcomes 4.7kb AA... |
| Stipple Bio | HealthtechB2b | - | - | Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led by RA Capital and a16z Bio; Pointillist platform id... |
| Strand Therapeutics | HealthtechB2b | - | - | Raised $153M Series B (Aug 2025). $256M total. Programmable mRNA with SignalLock tumor-sensing logic gates. STX-003 IV delivery entering clinic 2026. ... |
| Synchron | HealthtechHardwareStartupB2cNorth AmericaAi PoweredPlatform | - | - | Synchron pioneers the world's first endovascular BCI (Stentrode) enabling paralysis patients to control devices with thoughts; raised $200M Series D (... |
| Synkrino Biotherapeutics | HealthtechAi PoweredB2bStartupNorth America | - | - | Synkrino Biotherapeutics uses its AI and Immunology Discovery Engine (AIDE) to identify novel drug targets from immune patient tissue data; targets im... |
| Synthekine | HealthtechStartupNorth AmericaB2bManufacturingAnalyticsAi Powered | - | - | Synthekine engineers selective cytokine therapeutics for cancer and autoimmune disease; $289M raised, Phase 2 SYNERGY-101 trial underway, FDA Fast Tra... |
| Tempus | HealthtechB2bAi PoweredAnalyticsPlatformPublicSaasTechnologyNorth America | $1.27B | - | Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagn... |
| Tessera Therapeutics | HealthtechStartupNorth AmericaAi PoweredTechnology | - | - | Tessera Therapeutics is developing Gene Writing technology to insert large therapeutic sequences directly into the genome without double-strand DNA br... |
| Third Arc Bio | HealthtechB2b | - | - | Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecific T cell engager, CLDN6+) in Phase 1 solid tumors.... |
| Timberlyne Therapeutics | HealthtechB2b | - | - | Raised $180M Series A (Jan 2025). CM313 achieved 95% response rate in treatment-refractory ITP in NEJM-published data. Multi-indication 2026 pipeline.... |
| Trace Neuroscience | HealthtechB2b | - | - | Launched with $101M Series A (Third Rock, Atlas, GV, RA Capital). TRCN-1023 (ASO for UNC13A mRNA splicing) entered ALS clinical testing in early 2026 ... |
| Truvian Health | HealthtechB2bHardwareStartupNorth AmericaAi Powered | - | - | Truvian Health received FDA 510(k) clearance for its TruVerus benchtop blood analyzer in Dec 2025; raised $74M in July 2024 and is partnering with Sho... |
| Tune Therapeutics | HealthtechB2b | - | - | Epigenome editing company silencing disease-causing genes without permanent DNA cuts; raised $175M Series B led by Hevolution, NEA, and Regeneron Vent... |
| Turn Biotechnologies | HealthtechB2b | - | - | Raised $29M Series A. Acquired ARMMs vesicular delivery tech (Mar 2025). Delivers mRNA cocktails that transiently reprogram aged cells to youthful epi... |
| Twist Bioscience | B2bGlobalPublicHealthtechManufacturingPlatformAnalytics | $376M | - | Synthetic DNA manufacturing platform on silicon chips; $376M FY2025 revenue (+20% YoY). Supplies synthetic genes to 3,000+ customers across biotech, p... |
| Umoja Biopharma | HealthtechTechnologyStartupB2bGlobal | - | - | Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting T-cells in a single IV infusion, eliminating the ... |
| Uncommon Bio | HealthtechB2bStartupEuropeManufacturing | - | - | Uncommon Bio (formerly Higher Steaks) pivoted from cultivated pork to therapeutic biomanufacturing in 2024–2025; its cultivated meat platform was acqu... |
| Unity Biotechnology | HealthtechB2b | - | - | Positive 48-week Phase 2 BEHOLD data for UBX1325 in DME published in NEJM Evidence. Single-injection senolytic durability confirmed in diabetic macula... |
| Unlearn | Ai PoweredHealthtechB2bSaasStartupNorth AmericaAnalytics | - | - | AI digital twin platform (TwinRCT) replacing placebo arms in clinical trials. $100M+ raised ($50M rounds x2); EMA-qualified PROCOVA for Phase 2/3; FDA... |
| Verdiva Bio | HealthtechTechnologyStartupB2bGlobal | - | - | Verdiva Bio raised $200M in 2025 for next-generation oral GLP-1 receptor agonists designed to match injectable semaglutide efficacy with once-daily or... |
| Verve Therapeutics | StartupTechnologyHealthtechPublicB2b | - | - | Verve Therapeutics develops single-course gene editing medicines for cardiovascular disease, aiming to permanently lower LDL cholesterol with one trea... |
| Vial | B2bHealthtechSaasPlatformAi PoweredNorth AmericaStartupServicesAnalytics | - | - | Vial is a tech-enabled CRO that converts dermatology and ophthalmology clinics into research sites, handling regulatory administration, equipment prov... |
| Vima Therapeutics | HealthtechB2b | - | - | Raised $100M Series A extended ($60M + $40M add-on after clinical data) from Atlas, Frazier, Access Industries. Only oral drug in development for isol... |
| Viridian Biometals | HealthtechAi PoweredStartupAsia PacificB2b | - | - | Viridian Biometals is an Australian biotech developing metal-based cancer therapies using AI-assisted medicinal chemistry; focuses on copper and bismu... |
| Visby Medical | B2bB2cHealthtechHardwareTechnologyNorth AmericaStartupAi Powered | - | - | Visby Medical makes single-use handheld PCR diagnostic devices for point-of-care testing; received FDA EUA for COVID-19, flu A/B, and RSV tests; raise... |
| Vivtex | HealthtechB2b | - | - | Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer ... |
| Vizgen | HealthtechAi PoweredStartupNorth AmericaB2bHardwareAnalytics | - | - | Vizgen is a Cambridge MA life sciences company commercializing MERSCOPE, a spatial genomics platform based on MERFISH technology licensed from Harvard... |
Total Brands
198
Signal Strength
56% Strong
110871
Last Updated
May 2026